Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI-characterized prostates.

Autor: Olivier J; Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Department of Urology, Hospital Huriez, University Lille Nord de France, Lille, France.; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom., Stavrinides V; Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom., Kay J; Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom., Freeman A; Department of Pathology, UCLH NHS Foundation Trust, London, United Kingdom., Pye H; Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom., Ahmed Z; Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom., Carmona Echeverria L; Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom., Heavey S; Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom., Simmons LAM; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Department of Urology, UCLH NHS Foundation Trust, London, United Kingdom., Kanthabalan A; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Department of Urology, UCLH NHS Foundation Trust, London, United Kingdom., Arya M; Department of Urology, UCLH NHS Foundation Trust, London, United Kingdom., Briggs T; Department of Urology, UCLH NHS Foundation Trust, London, United Kingdom.; Department of Urology, The Royal Free London NHS Foundation Trust, London, United Kingdom., Barratt D; Department of Computer Science, Centre for Medical Imaging and Computing, University College London, London, United Kingdom., Charman SC; Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom.; Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom., Gelister J; Department of Urology, The Royal Free London NHS Foundation Trust, London, United Kingdom., Hawkes D; Department of Computer Science, Centre for Medical Imaging and Computing, University College London, London, United Kingdom., Hu Y; Department of Computer Science, Centre for Medical Imaging and Computing, University College London, London, United Kingdom., Jameson C; Department of Pathology, UCLH NHS Foundation Trust, London, United Kingdom., McCartan N; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Department of Urology, UCLH NHS Foundation Trust, London, United Kingdom., Punwani S; Faculty of Medicine, Department of Radiology, UCLH NHS Foundation Trust, London, United Kingdom., van der Muelen J; Department of Pathology, UCLH NHS Foundation Trust, London, United Kingdom.; Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom., Moore C; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Department of Urology, UCLH NHS Foundation Trust, London, United Kingdom., Emberton M; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Department of Urology, UCLH NHS Foundation Trust, London, United Kingdom., Ahmed HU; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., Whitaker HC; Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, United Kingdom.; Faculty of Medical Sciences, Division of Surgery and Interventional Science, University College London, London, United Kingdom.

Publikováno v: The Prostate [Prostate] 2018 Dec; Vol. 78 (16), pp. 1229-1237. Date of Electronic Publication: 2018 Aug 02.

Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data.

Autor: Blas, Leandro¹ (AUTHOR), Shiota, Masaki¹ (AUTHOR) shiota.masaki.101@m.kyushu-u.ac.jp, Eto, Masatoshi¹ (AUTHOR)

Publikováno v: Cancers. Sep2022, Vol. 14 Issue 17, p4161. 17p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial.

Autor: Pye, Hayley¹ (AUTHOR) joseph.norris@ucl.ac.uk, Singh, Saurabh^2,3 (AUTHOR) alex.kirkham@uclh.nhs.uk, Norris, Joseph M.^1,4 (AUTHOR) alistair.grey@nhs.net, Carmona Echeverria, Lina M.^1,4 (AUTHOR) v.stavrinides@ucl.ac.uk, Stavrinides, Vasilis^1,4 (AUTHOR) s.heavey@ucl.ac.uk, Grey, Alistair^4,5 (AUTHOR), Dinneen, Eoin^4,5 (AUTHOR), Pilavachi, Elly^2,3 (AUTHOR) clare.allen@uclh.nhs.uk, Clemente, Joey^2,3 (AUTHOR) j.clemente@nhs.net, Heavey, Susan¹ (AUTHOR) u.stopka-farooqui@ucl.ac.uk, Stopka-Farooqui, Urszula¹ (AUTHOR) b.simpson@ucl.ac.uk, Simpson, Benjamin S.¹ (AUTHOR) m.emberton@ucl.ac.uk, Bonet-Carne, Elisenda⁶ (AUTHOR) e.bonet-carne@ucl.ac.uk, Patel, Dominic⁷ (AUTHOR) dominic.patel.11@ucl.ac.uk, Barker, Peter⁸ (AUTHOR) peter.barker@addenbrookes.nhs.uk, Burling, Keith⁸ (AUTHOR) kab45@cam.ac.uk, Stevens, Nicola^2,3 (AUTHOR) nicola.showell1@nhs.net, Ng, Tony⁹ (AUTHOR) tony.ng@kcl.ac.uk, Panagiotaki, Eleftheria⁶ (AUTHOR) panagio@cs.ucl.ac.uk, Hawkes, David¹⁰ (AUTHOR) d.hawkes@ucl.ac.uk

Publikováno v: Cancers. Apr2021, Vol. 13 Issue 8, p1985. 1p.